On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

SOUTH SAN FRANCISCO - CERo Therapeutics Holdings, Inc. (NASDAQ:CERO), an immunotherapy company specializing in engineered T cell therapeutics, has announced a series of strategic moves aimed at ...